Since the exclusion of somatic causes is necessary for somatoform disorders (SMD) to be diagnosed, there is little information on the prevalence of such disorders in the community. As the method we have previously developed [general practitioners (GPs) with psychiatric training who interview samples representative of the general population] seemed to be appropriate to deal with the problem, we carried out a community survey focused on somatoform disorders. The prevalence rates of DSM-III-R somatoform disorders were studied in two wards of the city of Florence. In order to be representative of the general population, 673 subjects randomly selected were interviewed by their own GP. Four GPs, all with specific training in psychiatry, participated in the interviewing process. The 1-year prevalence figures were as follows: 0.7% body dysmorphic disorder; 4.5% hypochondriasis; 0.6% somatoform pain disorder; 0.3% conversion disorder; 0.7% somatization disorder; 13.8% undifferentiated somatoform disorder. No specific comorbidity was found between somatoform disorders and mood or anxiety disorders. Although the sample investigated was small, this study may be seen as one of the first in an area where knowledge is still scant. The prevalence rates of somatoform disorders were generally found to be slightly lower than expected.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/BF00800664 | DOI Listing |
PLoS One
January 2025
Department of Clinical Psychology, University of Dhaka, Bangladesh.
Background: The absence of a reliable and valid Bangla instrument for measuring somatic symptom disorder hinders research and clinical activities in Bangladesh. The present study aimed at translating and validating the Somatic Symptom Disorder-B criteria (SSD-12).
Method: A cross-sectional design was used with purposively selected clinical (n = 100) and non-clinical (n = 100) samples.
Background: Functional somatic syndromes are common in primary care and represent a challenge for general practitioners (GPs), with a risk of deterioration in the doctor-patient relationship, and of compassion fatigue on the part of the physician. Little is known about how to teach better management of these symptoms.
Methods: The aim of our scientific team was to develop a training session about functional somatic syndromes for GPs, with the objective to improve the therapeutic attitude of the participants.
Neuroimage
January 2025
Department of Psychosomatic Medicine and Psychotherapy, Medical Faculty, Heinrich-Heine University Duesseldorf, Bergische Landstraße 2, 40629 Duesseldorf, Germany.
Despite their high prevalence, somatoform pain disorders are often not recognized early enough, not diagnosed reliably enough and not treated appropriately. Patients often experience a high level of suffering and the feeling of not being understood. For the medical care system, the symptoms represent a diagnostic and therapeutic challenge.
View Article and Find Full Text PDFBMC Psychiatry
January 2025
Department of Neurology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, Guangdong, China.
Background: The neurasthenia-depression controversy has lasted for several decades. It is challenging to solve the argument by symptoms alone for syndrome-based disease classification. Our aim was to identify objective electroencephalography (EEG) measures that can differentiate neurasthenia from major depressive disorder (MDD).
View Article and Find Full Text PDFPain Rep
February 2025
Department Psychosomatic Medicine and Psychotherapy, Technical University Munich, Munich, Germany.
Introduction: The debate addressing the classification of chronic widespread pain as a physical disorder (fibromyalgia syndrome) [FMS] or a somatoform disorder according to psychiatric classification systems has continued for decades.
Objectives: The review aims to line out the new perspectives introduced by the 11th version of the International Classification of Diseases (ICD 11) of the World Health Organization (WHO).
Methods: Critical review of the classification criteria of fibromyalgia syndrome and bodily distress disorder in ICD 11.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!